A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-part Study of Orally Administered JNJ-54257099 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1) and Food-effect (Part 2) in Healthy Subjects, and Multiple Doses in Subjects With Chronic Hepatitis C Infection (Part 3)
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs AL 704 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Alios BioPharma
- 28 Jan 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 21 Dec 2015 According to Medivir media release, company has terminated the development of this drug based upon the acceptable safety and pharmacokinetics results of this trial.
- 03 Aug 2015 Status changed from planning to recruiting according to ClinicalTrials.gov record.